In a clinical scenario characterized by a NET G3 (Ki-67 35%), where the initiated systemic first-line therapy with TEM/CAP had to be discontinued due to side effects, patient preference, and the documented tumor progress, most participants supported a switch to PRRT (41.9%, n = 31). This evidence concerns the gene MKI67 and neoplasm.